Patent · US Active

EBNA1 inhibitors and their method of use

US10421718B2 · kind B2 · utility

0Cited by

5References

24Claims

0Family size

Assignee

The Wistar Institute of Anatomy and Biology · US

Inventors

Troy E. Messick · Upper Darby, US
Garry Robert Smith · Royersford, US
Allen B. Reitz · Lansdale, US
Paul Lieberman · Torrance, US
Mark McDonnell · Lansdale, US
Yan Zhang · Fort Washington, US
Venkata Velvadapu · Ankeny, US

Key dates

Filing date	Nov 16, 2017
Grant date	Sep 24, 2019
Priority date	—
Expiry date	Nov 16, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07C2601/02
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Pharmaceutical compositions of the invention comprise EBNA1 inhibitors useful for the treatment of diseases caused by EBNA1 activity such as cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and rheumatoid arthritis. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by lytic Epstein-Barr Virus (EBV) infection.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.